Blockchain Registration Transaction Record

Onco-Innovations and Ifowonco Join Forces to Develop Oral LAG-3 Inhibitors for Cancer

Onco-Innovations signs LOI with Ifowonco to develop oral LAG-3 inhibitors, combining DDR and immunotherapy for enhanced cancer treatment. Learn about this promising collaboration.

This collaboration between Onco-Innovations and Ifowonco could revolutionize cancer treatment by combining two cutting-edge approaches: DDR inhibition and LAG-3 blockade. If successful, this oral small-molecule therapy could provide a more convenient alternative to current intravenous monoclonal antibodies, potentially improving patient outcomes and quality of life. For investors, this strategic move positions Onco-Innovations at the forefront of next-generation cancer immunotherapy, offering significant growth potential as the company expands its pipeline and tackles solid tumours more effectively.